217 related articles for article (PubMed ID: 22109348)
1. A review of the rationale for additional therapeutic interventions to attain lower LDL-C when statin therapy is not enough.
Shanes JG
Curr Atheroscler Rep; 2012 Feb; 14(1):33-40. PubMed ID: 22109348
[TBL] [Abstract][Full Text] [Related]
2. Managing dyslipidemia in the high-risk patient.
Stein EA
Am J Cardiol; 2002 Mar; 89(5A):50C-57C. PubMed ID: 11900720
[TBL] [Abstract][Full Text] [Related]
3. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
Hou R; Goldberg AC
Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513
[TBL] [Abstract][Full Text] [Related]
4. Management of the patient with statin intolerance.
Vandenberg BF; Robinson J
Curr Atheroscler Rep; 2010 Jan; 12(1):48-57. PubMed ID: 20425271
[TBL] [Abstract][Full Text] [Related]
5. Statin and ezetimibe combination therapy in cardiovascular disease.
Dembowski E; Davidson MH
Curr Opin Endocrinol Diabetes Obes; 2009 Apr; 16(2):183-8. PubMed ID: 19262375
[TBL] [Abstract][Full Text] [Related]
6. Overview of pharmacologic therapy for the treatment of dyslipidemia.
Lipsy RJ
J Manag Care Pharm; 2003; 9(1 Suppl):9-12. PubMed ID: 14613353
[TBL] [Abstract][Full Text] [Related]
7. A Meta-Analysis Assessing Additional LDL-C Reduction from Addition of a Bile Acid Sequestrant to Statin Therapy.
Alder M; Bavishi A; Zumpf K; Peterson J; Stone NJ
Am J Med; 2020 Nov; 133(11):1322-1327. PubMed ID: 32416177
[TBL] [Abstract][Full Text] [Related]
8. Direct comparison of a dietary portfolio of cholesterol-lowering foods with a statin in hypercholesterolemic participants.
Jenkins DJ; Kendall CW; Marchie A; Faulkner DA; Wong JM; de Souza R; Emam A; Parker TL; Vidgen E; Trautwein EA; Lapsley KG; Josse RG; Leiter LA; Singer W; Connelly PW
Am J Clin Nutr; 2005 Feb; 81(2):380-7. PubMed ID: 15699225
[TBL] [Abstract][Full Text] [Related]
9. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial.
Pearson TA; Denke MA; McBride PE; Battisti WP; Brady WE; Palmisano J
Mayo Clin Proc; 2005 May; 80(5):587-95. PubMed ID: 15887425
[TBL] [Abstract][Full Text] [Related]
10. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease.
Toth PP; Foody JM; Tomassini JE; Sajjan SG; Ramey DR; Neff DR; Tershakovec AM; Hu XH; Tunceli K
J Clin Lipidol; 2014; 8(1):107-16. PubMed ID: 24528691
[TBL] [Abstract][Full Text] [Related]
12. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin.
Gazi IF; Daskalopoulou SS; Nair DR; Mikhailidis DP
Curr Med Res Opin; 2007 Sep; 23(9):2183-92. PubMed ID: 17692154
[TBL] [Abstract][Full Text] [Related]
13. Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations.
Adhyaru BB; Jacobson TA
Curr Atheroscler Rep; 2017 Jun; 19(6):29. PubMed ID: 28500517
[TBL] [Abstract][Full Text] [Related]
14. Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol.
Gotto AM; Farmer JA
Nat Clin Pract Cardiovasc Med; 2006 Dec; 3(12):664-72. PubMed ID: 17122799
[TBL] [Abstract][Full Text] [Related]
15. A multicentre, open-label, observational local study to evaluate the low-density lipoprotein cholesterol-lowering effect of ezetimibe as prescribed in daily routine practice in the South African population.
Raal F; Schamroth C; Patel J; Becker P
Cardiovasc J Afr; 2007; 18(5):325-9. PubMed ID: 17985033
[TBL] [Abstract][Full Text] [Related]
16. Statin combination therapy and cardiovascular risk reduction.
Toth PP; Farnier M; Tomassini JE; Foody JM; Tershakovec AM
Future Cardiol; 2016 May; 12(3):289-315. PubMed ID: 27079178
[TBL] [Abstract][Full Text] [Related]
17. Perspectives on low-density lipoprotein cholesterol goal achievement.
Catapano AL
Curr Med Res Opin; 2009 Feb; 25(2):431-47. PubMed ID: 19192988
[TBL] [Abstract][Full Text] [Related]
18. 2017 Taiwan lipid guidelines for high risk patients.
Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
[TBL] [Abstract][Full Text] [Related]
19. HDL-C: role as a risk modifier.
Barter P
Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
[TBL] [Abstract][Full Text] [Related]
20. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
Daskalopoulou SS; Mikhailidis DP
Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
